Lv52
970 积分 2022-01-04 加入
T-cell Engagers in Prostate Cancer
17天前
已完结
Perils and Problems in Bispecific T-Cell Engager Antibodies
17天前
已完结
IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer
17天前
已完结
Phage Display: A Laboratory Manual. Edited by C. F. Barbas III, D. R. Burton, J. K. Scott, and G. J. Silverman
23天前
已完结
Targeting Solid Tumors Using CD3 Bispecific Antibodies
24天前
已完结
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies
25天前
已完结
Back on the scene: Advances and challenges in CD3-related drugs in tumor therapy
25天前
已完结
T-cell-engaging bispecific antibodies in cancer
27天前
已完结
PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies
29天前
已完结
Back on the scene: Advances and challenges in CD3-related drugs in tumor therapy
1个月前
已完结
皖公网安备34019202002308
